Table of Contents

Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Global NASH Market, by Drug, 2025 (US$ Mn)

Chapter 3 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Overview 
3.1 Introduction
3.2 Epidemiology of Nonalcoholic Steatohepatitis (Qualitative Analysis)
     3.2.1 North America
     3.2.2 Europe
     3.2.3 Asia Pacific
     3.2.4 Rest of World
3.3 Diagnosis and Treatment of NASH (Qualitative Analysis)
3.4 Market Dynamics
     3.4.1 Drivers
     3.4.2 Restraints
     3.4.3 Opportunities

Chapter 4 Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type, 2015 – 2025 (US$ Mn)
4.1 Overview
4.2 Potential Drug Candidates in Phase III
     4.2.1 Obeticholic Acid (OCA)
     4.2.2 Aramchol (arachidyl amido cholanoic acid)
     4.2.3 Saroglitazar
     4.2.4 Elafibranor
4.3 Pipeline Analysis
     4.3.1 Tabular Representation of Phase I and Phase II Clinical Trials (Qualitative Analysis)
4.4 Target Population By Geography: NASH Market 

Chapter 5 Recommendations

Chapter 6 Company Profiles
6.1 AstraZeneca plc
     6.1.1 Company Overview
     6.1.2 Financial Overview
     6.1.3 Product Pipeline
     6.1.4 Business Strategies
     6.1.5 Recent Developments
6.2 Intercept Pharmaceuticals Inc.
6.3 Galmed Pharmaceuticals
6.4 GENFIT SA 
6.5 Gilead Sciences Inc. 
6.6 Zydus Cadila 
6.7 Immuron Ltd. 
6.8 Conatus Pharmaceuticals 
6.9 Tobira Therapeutics Inc.
6.10 Others

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Nonalcoholic Steatohepatitis Market

Buy Now